InnoCan Pharma Corporation (IP4.F)
- Previous Close
0.1810 - Open
0.1990 - Bid --
- Ask --
- Day's Range
0.1990 - 0.2030 - 52 Week Range
0.1204 - 0.3500 - Volume
31,188 - Avg. Volume
39,826 - Market Cap (intraday)
58.038M - Beta (5Y Monthly) 3.07
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments, Pharmaceuticals and Consumer Wellness. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for epilepsy and pain management. The company is also involved in the development and sale of CBD-integrated pharmaceuticals and topical products. In addition, it develops and markets a portfolio of self-care products for healthier lifestyle. The company offers its products under the Innocan Pharma, R&G Relief & Go, Shir, Synony, and Add On trade names. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.
innocanpharma.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: IP4.F
Performance Overview: IP4.F
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IP4.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IP4.F
Valuation Measures
Market Cap
51.75M
Enterprise Value
48.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.63
Price/Book (mrq)
13.20
Enterprise Value/Revenue
3.52
Enterprise Value/EBITDA
-12.03
Financial Highlights
Profitability and Income Statement
Profit Margin
-34.42%
Return on Assets (ttm)
-34.16%
Return on Equity (ttm)
-80.07%
Revenue (ttm)
13.66M
Net Income Avi to Common (ttm)
-4.7M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
3.88M
Total Debt/Equity (mrq)
0.75%
Levered Free Cash Flow (ttm)
-719.88k
Company Insights: IP4.F
IP4.F does not have Company Insights